Tyrosyl-DNA phosphodiesterase 2 (TDP2) repairs topoisomerase II (TOP2) mediated DNA damages and causes resistance to TOP2-targeted cancer therapy. Inhibiting TDP2 could sensitize cancer cells toward TOP2 inhibitors. However, potent TDP2 inhibitors with favorable physicochemical properties are not yet reported. Therefore, there is a need to search for novel molecular scaffolds capable of inhibiting TDP2. We report herein a new simple, robust, homogenous mix-and-read fluorescence biochemical assay based using humanized zebrafish TDP2 (14M_zTDP2), which provides biochemical and molecular structure basis for TDP2 inhibitor discovery. The assay was validated by screening a preselected library of 1600 compounds (Z′ ≥ 0.72) in a 384-well format, and by running in parallel gel-based assays with fluorescent DNA substrates. This library was curated via virtual high throughput screening (vHTS) of 460,000 compounds from Chembridge Library, using the crystal structure of the novel surrogate protein 14M_zTDP2. From this primary screening, we selected the best 32 compounds (2% of the library) to further assess their TDP2 inhibition potential, leading to the IC 50 determination of 10 compounds. Based on the dose-response curve profile, pan-assay interference compounds (PAINS) structure identification, physicochemical properties and efficiency parameters, two hit compounds, 11a and 19a, were tested using a novel secondary fluorescence gel-based assay. Preliminary structure-activity relationship (SAR) studies identified guanidine derivative 12a as an improved hit with a 6.4-fold increase in potency over the original HTS hit 11a. This study highlights the importance of the development of combination approaches (biochemistry, crystallography and high throughput screening) for the discovery of TDP2 inhibitors.
Introduction
Tyrosyl-DNA phosphodiesterase 2 (TDP2), also known as TNF receptor associated factor (TRAF) and TNF receptor associated protein (TTRAP) (Pype et al., 2000) and ETS1-associated protein 2 (EAPII) (Pei et al., 2003) , was the first human 5′-tyrosyl DNA phosphodiesterase identified (Cortes Ledesma et al., 2009 ). TDP2 plays a major role in DNA repair by specifically cleaving the 5′tyrosyl-DNA phosphodiester bond of stalled topoisomerase II (TOP2) cleavage complexes [reviewed in (Menon and Povirk, 2016; Pommier et al., 2014) ].
TOP2 resolves topological problems with double-stranded DNA during normal physiological processes, such as transcription and replication. Mechanistically, TOP2 acts by generating TOP2-DNA cleavage complexes (TOP2cc) featuring a covalent phosphotyrosine linkage between its active site tyrosine and the 5′ phosphate end at the site of DNA cleavage. These complexes are transient as TOP2 reseals cleaved DNA at the end of its catalytic cycle . However, under certain conditions, such as exposure to TOP2 poisons, TOP2cc become abortive (Fortune and Osheroff, 2000; Nitiss, 2009; Pommier, 2013) . Repair of abortive TOP2cc by cellular DNA repair machinery, particularly TDP2, can lead to cancer resistance to TOP2 poisons. By inhibiting TDP2, cancer cells could be sensitized toward treatment with TOP2 poisons, resulting in therapeutic efficacy with much lower doses of TOP2 poisons .
Several lines of evidence support the potential clinical benefits of specifically targeting TDP2 in cancer therapy: (i) TDP2-deleted cells show hypersensitivity to TOP2 poisons (Cortes Ledesma et al., 2009; Zeng et al., 2011) ; (ii) TDP2 knockout vertebrate cells show normal cell growth and knockout mice are viable without noticeable pathology, suggesting that TDP2 inhibitors could be well tolerated (Gomez-Herreros et al., 2013) ; (iii) the oncogenic role of overexpressed TDP2 has been established in several non-small-cell lung carcinoma cells (Li et al., 2011) , and TDP2 up-regulation attained by p53 gain-of-function mutation has been linked to TOP2 poison resistance in human lung cancer (Do et al., 2012) ; and (iv) tumor cells frequently lack parallel DNA repair pathways, which makes them more vulnerable to certain cancer chemotherapy (principle of synthetic lethality) (Curtin, 2012) , and more specifically to TOP2 inhibitors (Hoa et al., 2016; Maede et al., 2014; Pommier et al., 2014) .
In addition, TDP2 is also implicated in picornavirus and hepatitis B virus (HBV) infections during steps where cleavage of a 5′-phosphotyrosine covalent bond occurs. In particular, picornavirus uses TDP2, also known as VPg-unlinkase, to release the viral genomic RNA from VPg protein necessary during RNA replication (Maciejewski et al., 2016; Virgen-Slane et al., 2012) . HBV uses the DNA repair machinery of the infected cells to convert viral genomic relaxed circular DNA (RC-DNA) into covalently closed circular DNA (cccDNA) where TDP2 could play a role in releasing the viral P-protein from the 5′end of RC-DNA (Koniger et al., 2014) .
Since the discovery of TDP2 in 2009 (Cortes Ledesma et al., 2009) , only a few scaffolds have been identified possessing TDP2 inhibitory activity (Laev et al., 2016) : compound 1 (Ro 08-2750, Fig. 1 ) , deazaflavins (e.g. 2) (Hornyak et al., 2016; Marchand et al., 2016; Raoof et al., 2013) , isoquinoline-1,3-diones (e.g. 3) , the triple inhibitors TOP1/TDP1/TDP2 indenoisoquinolines (e.g. 4) (Beck et al., 2016; Wang et al., 2017) , compounds 5 (NSC375986), 6 (NSC114532) (Kossmann et al., 2016) and 7 (NSC111041) (Kont et al., 2016) . Deazaflavin derivatives are the only described TDP2 inhibitors with activities in the nanomolar range. However, their use as molecular probes in studying cellular functions and their potential as drug candidates are severely hindered by the poor cell permeability. (Hornyak et al., 2016) . Therefore, new scaffolds with good potencies and desirable physicochemical properties are highly desired.
The first reported methods developed to biochemically measure TDP2 activity employed gel-based assays (Cortes Ledesma et al., 2009; Gao et al., 2012; Zeng et al., 2011) . In addition to using radiolabeledsubstrates, these assays can be expensive and time-consuming, and thus may not be suitable for high-throughput screening (HTS). Colorimetric assays using T5NPP (Adhikari et al., 2011) or NPPP Thomson et al., 2013) as substrate have been developed, though difficulties in achieving enzyme inhibition above 75% were observed when NPPP was employed, and high enzyme concentration (30-36 nM) was required for both chromogenic assays. Since TDP2 prefers more physiologically relevant 5′-phosphotyrosyl oligonucleotides substrates over the small compound surrogates , a new colorimetric assay using a DNA substrate was reported . However, this particular assay required the addition of calf intestinal alkaline phosphatase (CIP) to cleave the phosphate group necessary for the reaction development. Recently, Hornyak et al. reported a fluorescence-based assay using a 13-mer oligonucleotide substrate with a 5′-tyrosine conjugated with FITC fluorophore and an enzyme concentration much lower than the chromogenic assays (50 pM) (Hornyak et al., 2016) . However, the TR-FRET nature of this assay required the addition of trivalent metal ion sensor (Gyrasol technologies) to quench the fluorescence of the substrate while stopping the reaction, resulting in increased assay costs, and allowing only end-point quenched readings.
We report herein a new fluorescence-based assay allowing reading in both continuous and quenched modality. With quenched reaction protocol this new assay is amenable for HTS and requires low enzyme concentration. In addition, the continuous reaction reading allows easy detection of false positives due to the presence of fluorescent compounds, as well as kinetic data collection (Acker and Auld, 2014) . By employing a humanized zebrafish protein (14M_zTDP2) developed by our group, and whose crystal structure is included in this report, we screened a library of 1600 compounds preselected via virtual highthroughput screening (vHTS).
Materials and methods

Chemistry
All commercial chemicals were used as supplied unless otherwise indicated. Flash chromatography was performed on a Teledyne Combiflash RF-200 with RediSep columns (silica) and indicated mobile phase. All moisture sensitive reactions were performed under an inert atmosphere of ultrapure argon with oven-dried glassware. 1 H and 13 C NMR spectra were recorded on a Varian 600 MHz or Bruker 400 spectrometer. Mass data were acquired on an Agilent 6230 TOF LC/MS spectrometer capable of ESI and APCI ion sources. All tested compounds have a purity ≥95%.
2.1.1. General procedural for synthesis of 2, 2, 4-trimethyl dihydroquinolines (10)
To a solution of corresponding aniline 8 (10 mmol) in acetone (15 mL), was added catalytic InCl 3 (5 mol%) and the resulting mixture 
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European Journal of Pharmaceutical Sciences 118 (2018) 67-79 was stirred at 50°C for 12-24 h. The solvent was removed in vacuo and the crude was dissolved in CH 2 Cl 2 , washed with Na 2 CO 3 solution and brine, dried over Na 2 SO 4 and evaporated in vacuo to produce the crude product. Purification of the crude product using Combi flash with 0-40% hexane in ethyl acetate as eluent furnished the desired product in 40-65% yield. Adapted from .
2.1.1.1. 6-Methoxy-2,2,4-trimethyl-1,2-dihydroquinoline (10a). Yield: 40%; 1 H NMR (600 MHz, DMSO-d 6 ) δ 6.59-6.52 (m, 2H), 6.41 (d, J = 9.0 Hz, 1H), 5.38 (s, 1H), 5.31 (s, 1H), 3.64 (s, 3H), 1.88 (d, J = 0.8 Hz, 3H), 1.16 (s, 6H).
2.1.1.2. 6-Chloro-2,2,4-trimethyl-1,2-dihydroquinoline (10c) (Li et al., 2006 To a solution of 10 (2.46 mmol) in water (5 mL), was added cyanoguanidine (2.46 mmol), concentrated HCl (1 mL) and the resulting mixture was stirred under reflux for 4 h. The hot mixture was decanted from oils, cooled and stirred continuously by treating with concentrated KOH until a pH of 10-11 was obtained. The resulting precipitate was filtered and washed several times with isopropanol followed by recrystallization from ethanol gave the desired product in 55-62% yield. Adapted from (Rosowsky and Modest, 1972; Webb et al., 2003) . (Brown, 1965) . Yield: 62%; 1 H NMR (600 MHz, DMSO-d 6 ) δ 7.50 (d, J = 9.1 Hz, 1H), 7.35 (dd, J = 9.1, 2.6 Hz, 1H), 7.27 (d, J = 2.6 Hz, 1H), 6.98 (s, 2H), 4.13 (q, J = 6.9 Hz, 2H), 2.69 (s, 3H), 1.38 (t, J = 6.9 Hz, 3H).
13 C NMR (100 MHz, DMSO-d 6 ) δ 167. 0, 159.0, 154.0, 145.5, 127.3, 125.1, 119.4, 104.8, 63.6, 21.7, 14.7 2.1.3. 2-((6-Methoxy-4-methylquinazolin-2-yl) amino)-5, 6-dimethylpyrimidin-4(3H)-one (12a) To a solution of 11a (0.10 g, 0.43 mmol) in minimal hot DMSO, was added ethyl 2-methylacetoacetate (0.07 mL, 0.52 mmol) and NaHCO 3 (0.044 g, 0.52 mmol). The reaction mixture was heated at 170°C until the disappearance of starting material. The solution was cooled, and water was added to precipitate the product which was collected by filtration, washed with acetone and water and dried to afford 12a (0.04 g, 30%) as a tan solid. 2.1.4. 2-((6-Methoxy-4-methylquinazolin-2-yl) amino) quinazolin-4(3H)-one (12b) (Guiles et al., 2009) A mixture of 11a (0.05 g, 0.22 mmol) and anthranilic acid (0.04 g, 0.26 mmol) in 1 mL of DMSO was heated at 170°C until the starting material disappeared. The reaction mixture was cooled, water was added, and the resulting product was filtered and washed with excess water. The crude mixture was recrystallized from chloroform to yield the desired product as colorless crystals (0.046 g, 64% (Shikhaliev et al., 2003) .
2.1.5. 1-(6-Methoxy-4-oxo-3,4-dihydroquinazolin-2-yl)guanidine (15) To a solution of anthranilic acid (0.1 g, 0.59 mmol) in 1 mL of 10% H 2 SO 4 , was added cyanoguanidine (0.075 g, 0.89 mmol) and refluxed for 60 min. The hot solid was precipitated and washed with excess water to furnish the desired product as colorless solid (0.077 g, 55% 2.1.6. 4-Amino-5-(furan-2-yl)-2,4-dihydro-3H-1,2,4-triazole-3-thione (18) (Koparır et al., 2004) To a solution of KOH (0.67 g, 11.89 mmol) in methanol (10 mL), was added furoic hydrazide (1.0 g, 7.92 mmol), CS 2 (0.72 mL, 11.89 mmol) and stirred at room temperature for 24 h and then ether was added and stirred the reaction mixture for another 2 h. The resulting solid was filtered, washed with cold methanol and ether and air dried. The solid was refluxed in excess of hydrazine hydrate (10 eq) for 5 h, cooled and poured into the acidic water (pH = 2). The solid was filtered and recrystallized from ethanol to produce the desired compound as colorless crystals (1.01 g, 70% over two steps).
1 H NMR (600 MHz, DMSO-d 6 ) δ 13.92 (s, 1H), 7.94 (dd, J = 1.8, 0.6 Hz, 1H), 7.39 (dd, J = 3.5, 0.6 Hz, 1H), 6.73 (dd, J = 3.5, 1.8 Hz, 1H), 5.83 (s, 2H). Adapted from (Khan et al., 2016) .
General procedure for the synthesis of 3-
To a mixture of 18 (1.0 mmol) in POCl 3 (5 mL), was added substituted benzoic acid (1.1 mmol) and refluxed for 6 h. The reaction mixture was cooled and slowly poured into crushed ice with stirring and neutralized with sodium bicarbonate. The precipitated solid was filtered, washed with cold water, dried, and recrystallized from ethanol to afford the desired compounds (19) as colorless crystals in 53-70% yield. Adapted from (Khan et al., 2016) . 19a) . Yield: 53%; 1 H NMR (600 MHz, DMSO-d 6 ) δ 8.04 (s, 1H), 7.84 (s, 1H), 7.78 (d, J = 7.6 Hz, 1H), 7.41 (t, J = 6.4 Hz, 2H), 6.82 (s, 1H), 2.35 (s, 3H), 2.33 (s, 3H).
13
C NMR (150 MHz, DMSO-d 6 ) δ 167. 5, 145.4, 142.5, 140.1, 139.3, 138.1, 130.6, 127.8, 126.5, 124.8, 112.2, 111.8, 19.60, 19.18 157.1, 154.8, 145.2, 140.2, 138.6, 134.4, 127.9, 121.7, 116.8, 113 
Curation of screening compounds
Structure based virtual screening (VS) is routinely performed in drug discovery involving in hit identification as a complementary approach to HTS which requires enormous cost, time and resources etc. A computational docking tool "Glide" (Friesner et al., 2004; Schrödinger, 2014b) from Schrodinger suite 2014-3 was used to perform virtual screening of larger commercial libraries which offers speed and accuracy in binding mode predictions and providing consistently high enrichment at every level. The docking protocol involves several steps which includes a) protein preparation: The crystal structure of z2hTDP2 cat (14M_zTDP2 cat ) was used for protein preparation in which bond orders and missing side chains were corrected, polar hydrogens are added, metal binding states were predicted, and the protein was minimized (pdb code: 6CA4). b) ligand preparation involving applying protonation and tautomeric states to the compounds from Chembridge library using lig prep (Schrödinger, 2014a) and Epik; c) Grid generation: creating a grid around the metal ions (Mn 2+ ) in the catalytic site and imposing a pharmacophore constraint with the metal ion to improve the chances of success in finding a hit molecule and d) docking of small molecule library (460 K) to the prepared protein of interest. The compound library (460 K) was first docked and ranked in Glide vHTS mode. The top 115 K molecules (25%) from vHTS mode were then docked and ranked using standard precision (SP) Glide (Friesner et al., 2004) . The resultant top 28,750 (25%) compounds from SP mode were then docked and ranked using the more accurate and computationally intensive extra-precision (XP) mode (Friesner et al., 2006) . The top 7200 compounds were selected for visual inspection and by applying a stringent constraint of physicochemical properties and synthetic tractability, we created a small sub-set of 1600 compounds for purchasing and biological evaluation. The screening protocol reported above was routinely and effectively utilized in the structure based virtual screening to aid hit-identification of various drug targets (Cain et al., 2014; Ravindranathan et al., 2010; Simmons et al., 2010; Umamaheswari et al., 2010) .
Biology
Compound library of 1600 compounds was purchased from Chembridge. Stock solutions between 2 and 20 mM were initially prepared and then sets of 320 compounds were plated and stored into 384-well plates at 2 mM in DMSO, mimicking the final HTS layout. Before screening, an intermediate plate was prepared consisting of compounds at 100 μM in reaction buffer. Substrate oligonucleotides 5′-(6-FAM-NHS)(5′-tyrosine)GATCT(3′-BHQ-1)-3′, 5′-phosphotyrosine-GATCTAA AAGACT-3′-(6-FAM)-3′ and 5′-phosphotyrosine-GATCTA(Cy5)AAGA CTT-phosphate-3′ were purchased from Midland Certified Reagents.
Protein purification, crystallization and structure determination
The humanized zebrafish TDP2 catalytic domain (spanning amino acid residues 120 to 369; 14M_zTdp2 cat ) was expressed from a codonoptimized gene as a SUMO (Smt3)-fusion protein in the Escherichia coli strain BL21(DE3) and purified essentially as described (Shi et al., 2012) using nickel-affinity and size-exclusion chromatography steps. The first residue Asp120 was mutated to Ser to facilitate cleavage by the SUMOprotease Ulp1. The purified protein in 20 mM Tris-HCl (pH 7.4), 150 mM NaCl, 10 mM dithiothreitol was concentrated by ultrafiltration to~15 mg/mL, flash frozen in liquid nitrogen, and stored in −80°C. Human TDP2 catalytic domain (residues 110-362) was expressed and purified similarly, except that SUMO fused to the N-terminus was kept uncleaved to mitigate the lower solubility of the human enzyme. 14M_zTdp2 cat was crystallized by the hanging drop vapor diffusion method using a reservoir solution consisting of 22% polyethylene glycol 3350, 75 mM sodium malonate (pH 7.0), and 0.2 M NaCl. The crystals typically grew as clusters of small and thin plates resembling a pinecone, and they had to be broken into small pieces before being flash frozen in liquid nitrogen for data collection. The crystals were screened, and x-ray diffraction data collected at the Advanced Photon Source NE-CAT 24 ID-E beamline at the wavelength of 0.979 Å. The diffraction datasets were processed using HKL2000 (Otwinowski and Minor, 1997) and XDS (Kabsch, 2010) . Structure was solved by molecular replacement using zebrafish TDP2 structure (PDB ID: 4F1H) as the search model using PHASER program (McCoy et al., 2007) . Three copies of TDP2 monomers were located in the asymmetric unit. Initial refinement of the molecular replacement solutions using REFMAC (Murshudov et al., 1997) yield R work and R free of 37% and 41% respectively. Subsequent refinement and model building were done using PHENIX (Adams et al., 2010) and COOT (Emsley et al., 2010) . Final R work and R free are 18.3% and 20.9%, respectively. The summary of data collection and model refinement statistics is shown in Table S1 (Supplementary material). Molecular graphic images were produced using PYMOL (www.pymol.org). The atomic coordinates and structure factor amplitudes have been deposited in the Protein Data Bank with accession code 6CA4. To 10 μL of enzyme solution, 10 μL of substrate was added to initiate reaction. The fluorescence of the product was measured using a SpectraMax M5e (Molecular Devices) (λ ex 285 nm; λ em 325 nm; λ cutoff 315 nm) in kinetic-mode at 25°C for 60-120 min. Assay DMSO tolerance was tested using 10 concentrations of DMSO (0-10%), and IC 50 determination of the control (2) was performed by using 12 serial (2-fold) dilution concentrations (0.92-2000 μM). Three consecutive days experiments were also performed to determine the basic "screenability" of the optimized conditions in the HTS format employed.
Screening of the compound library.
Compounds were screened at single concentration of 50 μM (final DMSO concentration of 2.5%) in two different plates. In each plate, maximum (wells containing enzyme, substrate and vehicle DMSO, 32 wells) and minimum controls (without enzyme, 24 wells) were included. To a black 384-well plate, 10 μL of compound solution (100 μM) was added, followed by addition of 5 μL of enzyme (25 pM, final concentration of 6.25 pM). After a pre-incubation period of 10 min, 5 μL of substrate 5′-(6-FAM-NHS)(5′-tyrosine)GATCT(3′-BHQ-1)-3′ (4 μM, final concentration of 1 μM) was added, and the reaction was allowed to proceed at 25°C for 60 min before being stopped by the addition of 5 μL ethylenediaminetetraacetic acid (EDTA) 0.5 mM, pH = 8. The fluorescence was measured using a SpectraMax M5e (Molecular Devices) (λ ex 285 nm; λ em 325 nm; λ cutoff 315 nm) at 25°C. Compounds were selected as hits in the HTS if they displayed at least 24% enzyme inhibition. In this analysis, two compounds exhibited a percent inhibition lower than −50% (TDP2 activity higher than 150%) and were excluded. In addition, due to solubility issues in DMSO, ten compounds were tested at concentrations lower than 50 μM.
For follow-up experiments, including IC 50 determinations, the same protocol was adopted, with the exception that the plates were analyzed in kinetic-mode, and the fluorescence monitored constantly for 60 min immediately after the reaction was started. When solubility allowed, hits were further analyzed at four concentrations in triplicate (25, 50, 100, and 200 μM), to test dose-dependent response and their potential interference with the assay. When 50% inhibition was reached up to 200 μM, IC 50 s were determined when possible.
Data analysis.
Throughout the assay optimization and validation steps the conditions tested were assessed by statistical parameters: Z′ factor, signal-to-background (S:B) and coefficients of variation (%CV) (Inglese et al., 2007; Zhang et al., 1999) . These parameters were also calculated during the HTS screen phase to ensure the quality of the data obtained.
In the equations above, μ max and μ min represent the mean values of fluorescence for maximum and minimum controls, respectively, and σ max and σ min represent their respective standard deviations.
Kinetic parameters (Km and Vmax) were calculated using a nonlinear Michaelis-Menten fitting of initial velocities as a function of substrate concentration (GraphPad Prism software). The inhibitory activity of the test compounds was calculated by normalizing the results plate-wise against the controls according to the following equation:
In the equation above, Fc is the fluorescence value from an individual test compound well, or in the case of dose-response experiments, the mean value of three technical replicates performed in the same plate. Data from the IC 50 determination experiments using 10 to 12 concentrations of inhibitor and vehicle-alone were fitted by GraphPad Prism software.
SUMO hTDP2
cat fluorescence-based biochemical assay
The reaction buffer used was composed by 50 mM Tris-HCl pH 7.4, 10 mM MgCl 2 , 80 mM KCl, 0.05% (v/v) Tween-20, and 1 mM DTT. To a black 384-well plate, 10 μL of compound solution (in reaction buffer, concentration 2-fold higher than the tested concentration) was added, followed by addition of 5 μL of SUMO hTDP2 cat enzyme (12.5 pM, final concentration of 3.13 pM). After a pre-incubation period of 10 min, 5 μL of substrate 5′-(6-FAM-NHS)(5′-tyrosine)GATCT(3′-BHQ-1)-3′ (1 μM, final concentration of 0.25 μM) was added, and the reaction was allowed to proceed at 25°C for 60 min. The fluorescence was measured, and the data was processed as described previously for 14M_zTDP2.
2.3.4. TDP2 gel-based assays. 2.3.4.1. Confirmatory assay. The reaction buffer used was composed by 50 mM Tris-HCl pH 7.4, 10 mM MgCl 2 , 80 mM KCl, and 1 mM DTT. To 6.5 μL of reaction buffer, 1 μL of enzyme solution (15 μM), and 0.5 μL of inhibitor solution (in DMSO, concentration 20-fold higher than the tested concentration) or DMSO was added and allowed to mix for 10 min. Then, 2 μL of 5′-YGATCTAAAAGACT-3′-(6-FAM)-3′ substrate (10 μM) was added, and the reaction was allowed to proceed at 25°C for 30 min before being stopped by the addition of 10 μL of formamide/ bromophenol blue loading buffer. Samples were boiled for 5 min, loaded into 15% polyacrylamide TBE + urea gel, and ran at 200 V for 45 min. Gels were then analyzed by BioRad Gel Doc EZ imager (blue tray 1708273).
2.3.4.2. WT_zTDP2 and mutants performance evaluation. TDP2 reactions were carried out similarly to describe previously with the following modifications. A 14-mer single-stranded oligonucleotide DNA substrate 5′-phosphotyrosine-GATCTA(Cy5)AAGACTT-3′-phosphate containing a 5′-phosphotyrosine (Cy5-Y14) and Cyanine5 (Cy5) dye incorporated in place of the nucleotide at position 7. The Cy5-Y14 was incubated at 40 nM with TDP2 in the absence or presence of an inhibitor for 15 min at room temperature in the reaction buffer containing 50 mM Tris-HCl, pH 7.5, 80 mM KCl, 5 mM MgCl 2 , 0.1 mM EDTA, 1 mM DTT, 40 μg/mL BSA, and 0.01% Tween 20. Reactions were terminated by the addition of 1 volume of gel loading buffer (5 mM EDTA solution in formamide). Polyacrylamide gels were cast in low fluorescence glass molds. Samples were subjected to a 16% denaturing PAGE. Gels were scanned directly in the mold on a Typhoon™ FLA 9500 (GE Healthcare) scanner using 635 nm excitation light. Densitometry analyses were performed using the ImageQuant software (GE Healthcare).
Results and discussion
Chemistry
Substituted 1,2-dihydro-2,2,4-trimethylquinoline derivatives (10, Scheme 1) were synthesized via modified Skraup reaction by treating substituted anilines with acetone in the presence of catalytic InCl 3 . Acid catalyzed reaction of compound 10 with cyanoguanidine produced the desired 4-methylquinazolyl-2-guanidines analogs (11) (Rosowsky and Modest, 1972; Webb et al., 2003) which was further derivatized by treating with diketoester or anthranilic acid in DMF at 170°C to furnish compounds 12a (LaPorte et al., 2014) and 12b (Shikhaliev et al., 2003) respectively. Compound 15 was obtained by the condensation of anthranilic acid derivative (13) with cyanoguanidine in refluxing 10% sulfuric acid in a moderate yield.
Reaction of furoic hydrazide (16, Scheme 2) with carbon disulfide in methanolic potassium hydroxide at room temperature afforded the dithiocarbazinate derivative (17) which subsequently underwent ring closure with an excess of hydrazine monohydrate to give the key triazole intermediate (18) (Khan et al., 2016) . Condensation of the aryl triazole (18) with substituted benzoic acids in phosphorus oxychloride under reflux provided access to the 1,2,4-triazolo[3,4-b][1,3,4]thiadiazoles (19) in moderate to excellent yields.
Development of a protein surrogate: 14M_zTDP2 cat
Previous attempts to obtain high-quality crystals of hTDP2 were unsuccessful due to limited solubility of the human protein. Conversely, zTDP2 is a much more soluble protein with suitable crystallographic behavior and that has provided structures with high resolution (Rao et al., 2016; Shi et al., 2012) . In addition, the catalytic domains of zebrafish and human TDP2 share high sequence identity (58%) warranting high degree of structural similarity (Shi et al., 2012 ). Yet, they do not respond similarly to the deazaflavin inhibitors . Thus, to obtain crystal structures relevant for the development of inhibitors against human TDP2, we took the approach to selectively humanize the active site and the DNA-binding groove of zTDP2 by amino acid substitutions and to make a surrogate for hTDP2 with adequate biochemical properties. Recently, Hornyak et al. similarly generated a humanized mouse TDP2 to overcome the problem of poor quality and reproducibility of the hTDP2 cat crystals (Hornyak et al., 2016) . We also took this approach to make mouse TDP2 sensitive to deazaflavin inhibitors . To achieve our goal of generating humanized zebrafish TDP2 proteins, several surface-exposed residues within~20 Å from the active center were changed to the corresponding human sequence. A series of zTDP2 catalytic domain constructs (residues 120-369) were generated. The three reported here included 6, 10 or 14 amino acid substitutions: 6 M (L136N, A139S, C239T, K240R, K314L, C322L), 10 M (L136N, A139S, C239T, K240R, K314L, Y318A, V319A, S320C, R321K, C322L) and 14 M (L136N, A139S, C239T, K240R, K309Q, K314L, T315G, V316I, P317T, Y318A, V319A, S320C, R321K, and C322L). To survey the performance of the WT_zTDP2 along with its generated 6 M, 10 M and 14 M mutants, we redesigned the assay based on use of 32 P-labeled DNA (Cortes Ledesma et al., 2009; Gao et al., 2012) to employ the fluorophore marker for oligomeric DNA detection. Using this gel-based assay with Cyanine5 (Cy5) dye incorporated into DNA substrate allows for speedier assays by eliminating required substrate 3′-32 P labeling reaction as well as cutting the gel handling steps, i.e. transferring from the mold, drying and exposing. With this assay we verified that only 14M_zTDP2 is catalytically as active as WT_zTDP2 ( Fig. 2A) , while 6 M and 10 M mutants turned out to be significantly less active ( Fig. 2A) . In addition, 14M_zTDP2 is as sensitive as hTDP2 to the known hTDP2 inhibitor 2: hTDP2 IC 50 = 40 nM Raoof et al., 2013) ; 14M_zTDP2 IC 50 = 63 nM; zTDP2 IC 50 > 100 μM (Fig. 2B ).
We were able to obtain high-quality crystals of 14M_zTDP2, which allowed structure solution at 1.62 Å resolution (Rfree = 20.9%). The crystal structure of our humanized TDP2 (14M_zTDP2) shows the active site containing a magnesium ion closely resembling those of mouse and zebrafish TDP2 (Fig. 3A) . Notably, an extended loop flanking the active site of 14M_zTDP2 appears to be highly flexible, where the residues 312-318 (corresponding to hTDP2 303-309) could not be modeled due to weak electron density. This flexible loop was previously shown to play roles in the binding of DNA (Schellenberg et al., 2012; Shi et al., 2012) and deazaflavin-based inhibitors (Hornyak et al., 2016) . A superposition of our structure of 14M_zTDP2 refined at 1.6 Å resolution with that of hTDP2 cat (3.1 Å resolution) shows high structural similarity as expected, with an r.m.s.d. of 0.47 Å for all backbone atoms (Fig. 3B) . We used this surrogate protein for in silico and biochemical studies.
Curation of screening compounds
The protein model used for the VHTS was based on the crystal structure of the humanized 14M_zTDP2 (6CA4). 460,000 compounds from Chembridge Library were then run in this model using Glide vHTS and scored based on active site binding. The top 7200 compounds were selected for visual inspection which concerns mostly physicochemical properties and synthetic tractability of ranked compounds. In the end, 1600 small molecules were purchased (Fig. 4) .
Assay optimization
We developed a fluorescence based assay suitable for high throughput screening in 384-well plates. The substrate employed consists of a fluorophore-quencher dual-labeled single stranded 5-mer oligonucleotide (Fig. 5) . Specifically, it contains a 5′-tyrosine residue labeled with the donor fluorophore FAM and a 3′-BHQ-1 molecule that Fig. 3. A) The active site of 14M_zTDP2. 2mFo-DFc electron density map contoured at 1.0σ is overlaid on the atomic model of the protein shown in sticks. Magnesium ion and coordinating water molecules are represented by small green and red spheres, respectively, with hydrogen bonds or metalcoordinating interactions indicated by yellow dotted lines. Other water molecules are depicted by red crosses. Protein residues are labeled accordingly to the wild type zebrafish TDP2 sequence, with the numbering for the equivalent human TDP2 residues shown in parentheses. B) Superposition of hTDP2 (pdb code: 5J3P) and 14M_zTDP2 (pdb code: 6CA4) in orange and green, respectively, with key active site residues in sticks and labeled as follows: hTDP2 (black text on white background), 14M_zTDP2 (white text on grey background). (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.) 
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acts as a dark quencher. The close proximity between FAM and BHQ-1 in the intact substrate allows proper quenching of the energy emitted at 525 nm by FAM when excited at 485 nm. Cleavage of the phosphodiester 5′-phosphotyrosine bond mediated by TDP2 liberates the fluorophore from the quencher effect, and an increase in fluorescence is observed. Therefore, TDP2 activity can be monitored as a function of the fluorescence measured. We started the optimization by varying protein concentration (0-800 pM) with a fixed amount of substrate (1 μM) over a period of 60 min. This assay allowed us to determine a starting enzyme concentration (6.25 pM) for subsequent kinetic studies that ensured linearity of the fluorescence measured over the duration of the assay (Fig. 6A) To choose the appropriate substrate concentration, we then performed experiments with different substrate amounts (0-50 μM) with the enzyme concentration selected in the preceding step to determine the Michaelis-Menten steady-state kinetic parameters (Km and Vmax) (Fig. 6B) . We decided to maintain the sub-Km substrate concentration tested previously (1 μM, 0.25 × Km) that also allowed a 
good signal-to-background ratio (10:1), with a low substrate conversion (10.1 ± 1.8%) (Fig. 6C ). In addition, under the established conditions, the assay showed a DMSO tolerance up to 2.5% without significant signal loss (fluorescence variability < 5% from control without DMSO).
To verify the accuracy of the inhibition measurements and to confirm the adequate surrogacy of 14M_TDP2 cat protein, we determined the IC 50 of deazaflavin 2, which has been extensively studied in different biochemical assays (NPPP chromogenic assay IC 50 = 40 nM ; gel-based assay IC 50 = 40 ± 3 nM ; fluorescence-based assay IC 50 = 19 ± 3.2 nM (Hornyak et al., 2016) ).
We obtained an IC 50 of 40.5 ± 2.7 nM which is in accordance with literature ( Fig. 6D ).
Good assay reproducibility and robustness is characterized by high Z′-factors (between 0.5 and 1), low coefficients of variance (lower than 15%) and consistent signal to background (S:B) windows (Inglese et al., 2007; Zhang et al., 1999) . Three consecutive days experiments mimicking the HTS conditions revealed a 0.72 ≤ Z′ ≤ 0.81, intra-plate and inter-plate CV < 10%, and S:B of 9-10.
HTS and preliminary SAR
A library of 1600 compounds previously curated via virtual screening was screened at a single concentration of 50 μM (Fig. 7) . Z′-factors between 0.72 and 0.84 were obtained for all plates, and daily intra-plate and inter-plate CV < 10%. From this library screening, 32 compounds (2% of the library) were selected for further studies (inhibition ≥24%). First, preliminary studies consisting in experiments involving four compound concentrations (25, 50, 100, and 200 μM, when solubility allowed) were performed, and then for hits with associated dose-dependent inhibition, IC 50 values were calculated (Table 1 , Fig. 8) . To obtain potentially better lead compounds, we eliminated all hits with a steep dose-response curve with slopes > 2 (22b, 24, 25, Fig. 8A ), and compounds containing moieties associated with pan assay interference compounds (PAINS). These types of structure are linked to promiscuous bioactivity due to their reactivity nature rather than desired enzyme inhibition (20, 26, 28 , Fig. 8B ) (Baell and Holloway, 2010; Dahlin and Walters, 2016) .
To decide which molecules to move forward to preliminary SAR studies (Fig. 8C) , we analyzed their physicochemical properties and determined a few efficiency parameters: ligand efficiency (LE) (Hopkins et al., 2004) , lipophilic ligand efficiency (LLE) (Leeson and Springthorpe, 2007; Shultz, 2013) , and ligand efficiency dependent lipophilicity (LELP) (Keseru and Makara, 2009) (Table 2 ). Since TDP2 activities were in the two-three digits micromolar activity range, we European Journal of Pharmaceutical Sciences 118 (2018) 67-79 decided to increase the parameters constrains to the Lipinski rule-offive (Lipinski et al., 2001) to match with what it is typically observed in fragment-based drug design libraries, such as the rule-of-three: MW < 300 Da, normally corresponding to < 20 non-hydrogen atoms; ≤3 hydrogen-bond donors and acceptors, ≤3 rotatable bonds, cLogP ≤ 3, and polar surface area (PSA) ≤ 60 Å (Congreve et al., 2003; Jhoti et al., 2013) . In addition, a good hit in early optimization stages should detain a LLE and a LE of at least 2 and 0.3, respectively, with a LELP ≤ 10 ( Keseru and Makara, 2009; Leach et al., 2006) . The HTS hit closer to fulfill these requisites was compound 11a that showed better efficiency parameters despite its lower potency, due presumably to its lower clogP and molecular weight values. The second compound that we selected for further analysis was compound 19a that showed the second-best features in both efficiency parameters and rule-of-three violations.
To confirm the TDP2 inhibition potential of these two hits, we also designed an orthogonal fluorescence gel-based assay that employs human TDP2 cat . As observed in Fig. 9 both hits were able to inhibit the hTDP2 in the same extent as in the primary assay, further corroborating the good surrogacy of 14M_zTDP2 enzyme.
Recently new biological activities were described for 3,6-diaryl and heteroaryl derivatives of triazolo [3,4-b] [1,3,4]thiadiazole derivatives (19) such as antitubulin activity (Xu et al., 2017) , dCTP pyrophosphatase 1 inhibition (Llona-Minguez et al., 2017) , CYP1A1 inhibition (Joshi et al., 2017) , and anti-angiogenesis activity by inhibiting TIE-2 (Pan et al., 2015) . The observed TDP2 inhibitory activity of hit 19a was confirmed through resynthesizing and retesting (Table 3) . This enable us to test an additional 41 triazolo [3,4-b] [1,3,4]thiadiazole compounds to complement the 24 analogues already present in the 1600 compound library (Table S2 , supplementary material). The combined set of 65 compounds was screened at 100 μM. IC 50 determination was conducted for derivatives with > 50% inhibition at this concentration (19c-e). We Non-violations to the rule of three and to the efficiency parameters established are highlighted in grey. positive control 2 at IC 50 concentration; lanes 4-6: three 10-fold dilutions of hit compound 11a; lanes 7-9: three 10-fold dilutions of hit compound 19a; S: substrate; P: product. 3.5.2. 2-Guanidine-4-methylquinazoline derivatives 2-Guanidine-4-methylquinazoline analogues are associated with a range of biological activities, such as heme enzyme myeloperoxidase inhibition (Soubhye et al., 2017) , antibacterial activity by inhibiting translation (Komarova et al., 2017) , A type γ-aminobutyric acid receptors (GABA A R) antagonism (Xiao et al., 2013) , acid sensing ion channel ASIC3 activation (Yu et al., 2010) , and anti-H 2 -histamine activity (Pinelli et al., 1996) . Again, hit 11a was confirmed via resynthesizing and retesting (Table 4 ). The initial SAR study focusing on position 6 (11a-c) revealed that increasing the length of the ether side chain did not interfere significantly with the activity (11b vs. 11a), whereas changing the substituent to chloro abrogated completely the inhibitory activity up to 200 μM (11c vs. 11a). In addition, no inhibition was observed with the 4-ketone analogue (15) synthesized to probe position 4 of the hit compound. Four compounds with derivatization in the guanidine end were already present in the screening library (11d, 34a-c). However, pyrimidine derivatives (34a-c) were not able to produce 50% inhibition at 100 μM and higher concentrations were not achievable due to solubility limitations. Although aromatization of the guanidine did not lead to potency improvement, we decided to test pyrimidone derivatives due to their reported biological activities, such as STAT3 pathway inhibition (LaPorte et al., 2014), enhancement of zeste 2 (EZH2) inhibition (Wu et al., 2016) , and bacterial DNA polymerase III inhibition (Guiles et al., 2009 ). We purchased and tested two derivatives 12c-d. Both were at least 5-fold more active than the guanidine hit. This led to the synthesis and testing of two new pyrimidone derivatives (12a-b), with the 6-methoxy group of the original hit retained. All pyrimidone derivatives tested were found to be equipotent (IC 50 = 17-27 μM).
Lastly, the activity of the hit compounds, as well as the best synthesized guanidine derivative, was confirmed using human TDP2 enzyme in the same biochemical fluorescence-based assay, as similar potencies were observed (Table 5 ).
Conclusions
TDP2 inhibitors can be used to enhance TOP2-targeted drugs (etoposide, doxorubicin, daunorubicin), which are widely used as anticancer therapies. In addition, TDP2 inhibitors could provide novel antiviral strategies for targeting picornaviruses and HBV. To facilitate the discovery of novel TDP2 inhibitor scaffolds, we report here the generation of a humanized zebrafish TDP2 (14M_zTDP2), which provides further structural insights on the TDP2 catalytic site. We show that the 14 M enzyme is sensitive to the reference TDP2 inhibitors of the deazaflavin class, and is readily amenable to biochemical and drug screening studies. Indeed, we developed a new fluorescence-based a Values are the means of three independent experiments performed in triplicate.
C.J.A. Ribeiro et al. European Journal of Pharmaceutical Sciences 118 (2018) 67-79 biochemical assay suitable for 384-well plate screenings with a simple, homogeneous "mix and read" procedure that allows readings of both continuous and quenched reactions. This assay was used to screen 1600 commercial compounds preselected from 460,000 Cambridge Library compounds through vHTS. Selected hits (11a and 19a) were confirmed using a novel secondary gel-based fluorescence assay with resynthesized samples. Preliminary SAR studies identified guanidine derivative 12a (hTDP2 IC 50 = 17.7 μM) as an improved inhibitor over the original hit 11a (hTDP2 IC 50 = 113 μM). These results support our new assays (chemical screening and crystallographic analyses) as tools in TDP2 inhibitor discovery.
